Epigenetic modifications in breast cancer and their role in personalized medicine

American Journal of Pathology

Volumn 183, Issue 4, 2013, Pages 1052-1063

  Stefansson, Olafur A ^a   Esteller, Manel ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AURORA B KINASE; AZACITIDINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 1; CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR; HISTONE; HISTONE METHYLTRANSFERASE; INIPARIB; OLAPARIB; PROGESTERONE RECEPTOR; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; TAMOXIFEN; TRANSCRIPTION FACTOR RUNX1; UNTRANSLATED RNA; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ALU SEQUENCE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CELL DIVISION; CELL SURVIVAL; CHROMATIN; CHROMATIN STRUCTURE; CONSTITUTIVE HETEROCHROMATIN; CPG ISLAND; DEMETHYLATION; DNA END JOINING REPAIR; DNA HELIX; DNA METHYLATION; DNA REPAIR; DNA SEQUENCE; DRUG RESPONSE; DRUG SENSITIVITY; EMBRYONIC STEM CELL; EPIGENETICS; GENE DOSAGE; GENE EXPRESSION; GENE INACTIVATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; GLIOMA; HUMAN; HUMAN GENOME; LETHALITY; MORPHOGENESIS; NUCLEOSOME; ONCOGENE; OVARY CANCER; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RETROPOSON; REVIEW; TREATMENT RESPONSE; TUMOR GENE; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BREAST NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION;

EID: 84884545112     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.04.033     Document Type: Review

References (111)

1. F. Lalloo, and D.G. Evans Familial breast cancer Clin Genet 82 2012 105 114
2. D. Fanale, V. Amodeo, L.R. Corsini, S. Rizzo, V. Bazan, and A. Russo Breast cancer genome-wide association studies: there is strength in numbers Oncogene 31 2012 2121 2128
3. K. Gudmundsdottir, and A. Ashworth The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability Oncogene 25 2006 5864 5874
4. M. Esteller Epigenetics in cancer N Engl J Med 358 2008 1148 1159
5. A.P. Feinberg Phenotypic plasticity and the epigenetics of human disease Nature 447 2007 433 440
6. J.G. Herman, F. Latif, Y. Weng, M.I. Lerman, B. Zbar, S. Liu, D. Samid, D.S. Duan, J.R. Gnarra, W.M. Linehan, and S.B. Baylin Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma Proc Natl Acad Sci USA 91 1994 9700 9704
7. S. Jones, T.L. Wang, I.M. Shih, T.L. Mao, K. Nakayama, R. Roden, R. Glas, D. Slamon, L.A. Diaz Jr., B. Vogelstein, K.W. Kinzler, V.E. Velculescu, and N. Papadopoulos Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 330 2010 228 231
8. S. Jones, M. Li, D.W. Parsons, X. Zhang, J. Wesseling, P. Kristel, M.K. Schmidt, S. Markowitz, H. Yan, D. Bigner, R.H. Hruban, J.R. Eshleman, C.A. Iacobuzio-Donahue, M. Goggins, A. Maitra, S.N. Malek, S. Powell, B. Vogelstein, K.W. Kinzler, V.E. Velculescu, and N. Papadopoulos Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types Hum Mutat 33 2012 100 103
9. H. Noushmehr, D.J. Weisenberger, K. Diefes, H.S. Phillips, K. Pujara, B.P. Berman, F. Pan, C.E. Pelloski, E.P. Sulman, K.P. Bhat, R.G. Verhaak, K.A. Hoadley, D.N. Hayes, C.M. Perou, H.K. Schmidt, L. Ding, R.K. Wilson, D. Van Den Berg, H. Shen, H. Bengtsson, P. Neuvial, L.M. Cope, J. Buckley, J.G. Herman, S.B. Baylin, P.W. Laird, K. Aldape Cancer Genome Atlas Research Network Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
10. P.J. Stephens, P.S. Tarpey, H. Davies, P. Van Loo, C. Greenman, D.C. Wedge Oslo Breast Cancer Consortium (OSBREAC) The landscape of cancer genes and mutational processes in breast cancer Nature 486 2012 400 404
11. I.W. Teng, P.C. Hou, K.D. Lee, P.Y. Chu, K.T. Yeh, V.X. Jin, M.J. Tseng, S.J. Tsai, Y.S. Chang, C.S. Wu, H.S. Sun, K.D. Tsai, L.B. Jeng, K.P. Nephew, T.H. Huang, S.H. Hsiao, and Y.W. Leu Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells Cancer Res 71 2011 4653 4663
12. A. Dobrovic, and D. Simpfendorfer Methylation of the BRCA1 gene in sporadic breast cancer Cancer Res 57 1997 3347 3350
13. J.C. Rice, H. Ozcelik, P. Maxeiner, I. Andrulis, and B.W. Futscher Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens Carcinogenesis 21 2000 1761 1765
14. M. Esteller, J.M. Silva, G. Dominguez, F. Bonilla, X. Matias-Guiu, E. Lerma, E. Bussaglia, J. Prat, I.C. Harkes, E.A. Repasky, E. Gabrielson, M. Schutte, S.B. Baylin, and J.G. Herman Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 2000 564 569
15. A. Catteau, W.H. Harris, C.F. Xu, and E. Solomon Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics Oncogene 18 1999 1957 1965
16. V. Birgisdottir, O.A. Stefansson, S.K. Bodvarsdottir, H. Hilmarsdottir, J.G. Jonasson, and J.E. Eyfjord Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer Breast Cancer Res 8 2006 R38
17. M. Esteller, J. Garcia-Foncillas, E. Andion, S.N. Goodman, O.F. Hidalgo, V. Vanaclocha, S.B. Baylin, and J.G. Herman Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [Erratum appeared in N Engl J Med 2000, 343:1740] N Engl J Med 343 2000 1350 1354
18. K. Masuda, K. Banno, M. Yanokura, K. Tsuji, Y. Kobayashi, I. Kisu, A. Ueki, W. Yamagami, H. Nomura, E. Tominaga, N. Susumu, and D. Aoki Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells Oncol Rep 28 2012 1146 1152
19. F.A. Sinicrope, and D.J. Sargent Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications Clin Cancer Res 18 2012 1506 1512
20. M. Esteller, R. Levine, S.B. Baylin, L.H. Ellenson, and J.G. Herman MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas Oncogene 17 1998 2413 2417
21. S.B. Baylin, and P.A. Jones A decade of exploring the cancer epigenome-biological and translational implications Nat Rev Cancer 11 2011 726 734
22. P.A. Jones Functions of DNA methylation: islands, start sites, gene bodies and beyond Nat Rev Genet 13 2012 484 492
23. F. Antequera, and A. Bird Number of CpG islands and genes in human and mouse Proc Natl Acad Sci USA 90 1993 11995 11999
24. K. Williams, J. Christensen, and K. Helin DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep 13 2011 28 35
25. F. Delhommeau, S. Dupont, V. Della Valle, C. James, S. Trannoy, A. Massé, O. Kosmider, J.P. Le Couedic, F. Robert, A. Alberdi, Y. Lécluse, I. Plo, F.J. Dreyfus, C. Marzac, N. Casadevall, C. Lacombe, S.P. Romana, P. Dessen, J. Soulier, F. Viguié, M. Fontenay, W. Vainchenker, and O.A. Bernard Mutation in TET2 in myeloid cancers N Engl J Med 360 2009 2289 2301
26. A.F. Fernandez, Y. Assenov, J.I. Martin-Subero, B. Balint, R. Siebert, and H. Taniguchi A DNA methylation fingerprint of 1628 human samples Genome Res 22 2012 407 419
27. S. Nik-Zainal, L.B. Alexandrov, D.C. Wedge, P. Van Loo, C.D. Greenman, K. Raine Breast Cancer Working Group of the International Cancer Genome Consortium Mutational processes molding the genomes of 21 breast cancers Cell 149 2012 979 993
28. B. Schuster-Böckler, and B. Lehner Chromatin organization is a major influence on regional mutation rates in human cancer cells Nature 488 2012 504 507
29. M. Esteller, M.F. Fraga, M. Guo, J. Garcia-Foncillas, I. Hedenfalk, A.K. Godwin, J. Trojan, C. Vaurs-Barrière, Y.J. Bignon, S. Ramus, J. Benitez, T. Caldes, Y. Akiyama, Y. Yuasa, V. Launonen, M.J. Canal, R. Rodriguez, G. Capella, M.A. Peinado, A. Borg, L.A. Aaltonen, B.A. Ponder, S.B. Baylin, and J.G. Herman DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis Hum Mol Genet 10 2001 3001 3007
30. M.O. Hoque, O. Topaloglu, S. Begum, R. Henrique, E. Rosenbaum, W. Van Criekinge, W.H. Westra, and D. Sidransky Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects J Clin Oncol 23 2005 6569 6575
31. J.G. Herman, J.R. Graff, S. Myöhänen, B.D. Nelkin, and S.B. Baylin Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA 93 1996 9821 9826
32. E. Dejeux, J.A. Rønneberg, H. Solvang, I. Bukholm, S. Geisler, T. Aas, I.G. Gut, A.L. Børresen-Dale, P.E. Lønning, V.N. Kristensen, and J. Tost DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response Mol Cancer 9 2010 68
33. A.A. Muggerud, J.A. Rønneberg, F. Wärnberg, J. Botling, F. Busato, J. Jovanovic, H. Solvang, I. Bukholm, A.L. Børresen-Dale, V.N. Kristensen, T. Sørlie, and J. Tost Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer Breast Cancer Res 12 2010 R3
34. Q.C. Lau, E. Raja, M. Salto-Tellez, Q. Liu, K. Ito, M. Inoue, T.C. Putti, M. Loh, T.K. Ko, C. Huang, K.N. Bhalla, T. Zhu, Y. Ito, and S. Sukumar RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer Cancer Res 66 2006 6512 6520
35. M.M. Subramaniam, J.Y. Chan, R. Soong, K. Ito, Y. Ito, K.G. Yeoh, M. Salto-Tellez, and T.C. Putti RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression Breast Cancer Res Treat 113 2009 113 121
36. M. Widschwendter, K.D. Siegmund, H.M. Müller, H. Fiegl, C. Marth, E. Müller-Holzner, P.A. Jones, and P.W. Laird Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen Cancer Res 64 2004 3807 3813
37. S. Maier, I. Nimmrich, T. Koenig, S. Eppenberger-Castori, I. Bohlmann, A. Paradiso, F. Spyratos, C. Thomssen, V. Mueller, J. Nährig, F. Schittulli, R. Kates, R. Lesche, I. Schwope, A. Kluth, A. Marx, J.W. Martens, J.A. Foekens, M. Schmitt, N. Harbeck European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients-technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group Eur J Cancer 43 2007 1679 1686
38. M. Esteller, P.G. Corn, J.M. Urena, E. Gabrielson, S.B. Baylin, and J.G. Herman Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia Cancer Res 58 1998 4515 4518
39. M.O. Hoque, Q. Feng, P. Toure, A. Dem, C.W. Critchlow, S.E. Hawes, T. Wood, C. Jeronimo, E. Rosenbaum, J. Stern, M. Yu, B. Trink, N.B. Kiviat, and D. Sidransky Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer J Clin Oncol 24 2006 4262 4269
40. G.C. Hon, R.D. Hawkins, O.L. Caballero, C. Lo, R. Lister, M. Pelizzola, A. Valsesia, Z. Ye, S. Kuan, L.E. Edsall, A.A. Camargo, B.J. Stevenson, J.R. Ecker, V. Bafna, R.L. Strausberg, A.J. Simpson, and B. Ren Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer Genome Res 22 2012 246 258
41. D. Pasini, P.A. Cloos, J. Walfridsson, L. Olsson, J.P. Bukowski, J.V. Johansen, M. Bak, N. Tommerup, J. Rappsilber, and K. Helin JARID2 regulates binding of the polycomb repressive complex 2 to target genes in ES cells Nature 464 2010 306 310
42. B.E. Bernstein, T.S. Mikkelsen, X. Xie, M. Kamal, D.J. Huebert, J. Cuff, B. Fry, A. Meissner, M. Wernig, K. Plath, R. Jaenisch, A. Wagschal, R. Feil, S.L. Schreiber, and E.S. Lander A bivalent chromatin structure marks key developmental genes in embryonic stem cells Cell 125 2006 315 326
43. E. Viré, C. Brenner, R. Deplus, L. Blanchon, M. Fraga, C. Didelot, L. Morey, A. Van Eynde, D. Bernard, J.M. Vanderwinden, M. Bollen, M. Esteller, L. Di Croce, Y. de Launoit, and F. Fuks The polycomb group protein EZH2 directly controls DNA methylation [Erratum appeared in Nature 2007, 446:824] Nature 439 2006 871 874
44. M. Esteller Non-coding RNAs in human disease Nat Rev Genet 12 2011 861 874
45. F. Aguilo, M.M. Zhou, and M.J. Walsh Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression Cancer Res 71 2011 5365 5369
46. K. Holm, C. Hegardt, J. Staaf, J. Vallon-Christersson, G. Jönsson, H. Olsson, A. Borg, and M. Ringnér Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns Breast Cancer Res 12 2010 R36
47. F. Fang, S. Turcan, A. Rimner, A. Kaufman, D. Giri, L.G. Morris, R. Shen, V. Seshan, Q. Mo, A. Heguy, S.B. Baylin, N. Ahuja, A. Viale, J. Massague, L. Norton, L.T. Vahdat, M.E. Moynahan, and T.A. Chan Breast cancer methylomes establish an epigenomic foundation for metastasis Sci Transl Med 3 2011 75ra25
48. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
49. R. Lister, M. Pelizzola, R.H. Dowen, R.D. Hawkins, G. Hon, J. Tonti-Filippini, J.R. Nery, L. Lee, Z. Ye, Q.M. Ngo, L. Edsall, J. Antosiewicz-Bourget, R. Stewart, V. Ruotti, A.H. Millar, J.A. Thomson, B. Ren, and J.R. Ecker Human DNA methylomes at base resolution show widespread epigenomic differences Nature 462 2009 315 322
50. M.R. Stratton, P.J. Campbell, and P.A. Futreal The cancer genome Nature 458 2009 719 724
51. N. Collins, R. McManus, R. Wooster, J. Mangion, S. Seal, S.R. Lakhani, W. Ormiston, P.A. Daly, D. Ford, D.F. Easton, and M.R. Stratton Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13 Oncogene 10 1995 1673 1675
52. S.A. Smith, D.F. Easton, D.G. Evans, and B.A. Ponder Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome Nat Genet 2 1992 128 131
53. Z. Barekati, R. Radpour, C. Kohler, B. Zhang, P. Toniolo, P. Lenner, Q. Lv, H. Zheng, and X.Y. Zhong Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations Hum Mol Genet 19 2010 2936 2946
54. N. Collins, R. Wooster, and M.R. Stratton Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers Br J Cancer 76 1997 1150 1156
55. N. Cucer, S. Taheri, E. Ok, and Y. Ozkul Methylation status of CpG islands at sites -59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer J Genet 87 2008 155 158
56. R. Pal, N. Srivastava, R. Chopra, S. Gochhait, P. Gupta, N. Prakash, G. Agarwal, and R.N. Bamezai Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology Mol Cancer 9 2010 303
57. A. Potapova, A.M. Hoffman, A.K. Godwin, T. Al-Saleem, and P. Cairns Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer Cancer Res 68 2008 998 1002
58. Q.N. Vo, W.J. Kim, L. Cvitanovic, D.A. Boudreau, D.G. Ginzinger, and K.D. Brown The ATM gene is a target for epigenetic silencing in locally advanced breast cancer [Erratum appeared in Oncogene 2005, 24:1964] Oncogene 23 2004 9432 9437
59. J.C. Brandes, H. Carraway, and J.G. Herman Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter [Erratum appeared in Oncogene 2007 Oct 11;26(46):6684] Oncogene 26 2007 6229 6237
60. O.A. Stefansson, J.G. Jonasson, K. Olafsdottir, H. Hilmarsdottir, G. Olafsdottir, M. Esteller, O.T. Johannsson, and J.E. Eyfjord CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer Epigenetics 6 2011 638 649
61. W.D. Foulkes, I.M. Stefansson, P.O. Chappuis, L.R. Bégin, J.R. Goffin, N. Wong, M. Trudel, and L.A. Akslen Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 2003 1482 1485
62. S. Furuta, X. Jiang, B. Gu, E. Cheng, P.L. Chen, and W.H. Lee Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells Proc Natl Acad Sci USA 102 2005 9176 9181
63. E. Lim, F. Vaillant, D. Wu, N.C. Forrest, B. Pal, A.H. Hart, M.L. Asselin-Labat, D.E. Gyorki, T. Ward, A. Partanen, F. Feleppa, L.I. Huschtscha, H.J. Thorne, kConFab, S.B. Fox, M. Yan, J.D. French, M.A. Brown, G.K. Smyth, J.E. Visvader, and G.J. Lindeman Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers Nat Med 15 2009 907 913
64. O.A. Stefansson, J.G. Jonasson, O.T. Johannsson, K. Olafsdottir, M. Steinarsdottir, S. Valgeirsdottir, and J.E. Eyfjord Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes [Erratum appeared in Breast Cancer Res 2009, 11:40] Breast Cancer Res 11 2009 R47
65. S.A. Joosse, K.I. Brandwijk, L. Mulder, J. Wesseling, J. Hannemann, and P.M. Nederlof Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors Genes Chromosomes Cancer 50 2011 71 81
66. L.H. Saal, S.K. Gruvberger-Saal, C. Persson, K. Lövgren, M. Jumppanen, J. Staaf, G. Jönsson, M.M. Pires, M. Maurer, K. Holm, S. Koujak, S. Subramaniyam, J. Vallon-Christersson, H. Olsson, T. Su, L. Memeo, T. Ludwig, S.P. Ethier, M. Krogh, M. Szabolcs, V.V. Murty, J. Isola, H. Hibshoosh, R. Parsons, and A. Borg Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair Nat Genet 40 2008 102 107
67. G. Jönsson, J. Staaf, J. Vallon-Christersson, M. Ringnér, S.K. Gruvberger-Saal, L.H. Saal, K. Holm, C. Hegardt, A. Arason, R. Fagerholm, C. Persson, D. Grabau, E. Johnsson, K. Lövgren, L. Magnusson, P. Heikkilä, B.A. Agnarsson, O.T. Johannsson, P. Malmström, M. Fernö, H. Olsson, N. Loman, H. Nevanlinna, R.B. Barkardottir, and Å. Borg The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer Cancer Res 72 2012 4028 4036
68. H. Holstege, S.A. Joosse, C.T. van Oostrom, P.M. Nederlof, A. de Vries, and J. Jonkers High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer Cancer Res 69 2009 3625 3633
69. M. Zeidler, S. Varambally, Q. Cao, A.M. Chinnaiyan, D.O. Ferguson, S.D. Merajver, and C.G. Kleer The polycomb group protein EZH2 impairs DNA repair in breast epithelial cells Neoplasia 7 2005 1011 1019
70. C.J. Chang, J.Y. Yang, W. Xia, C.T. Chen, X. Xie, C.H. Chao, W.A. Woodward, J.M. Hsu, G.N. Hortobagyi, and M.C. Hung EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling Cancer Cell 19 2011 86 100
71. X. Li, M.E. Gonzalez, K. Toy, T. Filzen, S.D. Merajver, and C.G. Kleer Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia Am J Pathol 175 2009 1246 1254
72. C.M. Perou, and A.L. Børresen-Dale Systems biology and genomics of breast cancer Cold Spring Harb Perspect Biol 3 2011 a003293
73. D.M. Chou, B. Adamson, N.E. Dephoure, X. Tan, A.C. Nottke, K.E. Hurov, S.P. Gygi, M.P. Colaiácovo, and S.J. Elledge A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage Proc Natl Acad Sci USA 107 2010 18475 18480
74. N. Ayoub, A.D. Jeyasekharan, J.A. Bernal, and A.R. Venkitaraman HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response Nature 453 2008 682 686
75. J. Puppe, R. Drost, X. Liu, S.A. Joosse, B. Evers, P. Cornelissen-Steijger, P. Nederlof, Q. Yu, J. Jonkers, M. van Lohuizen, and A.M. Pietersen BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to polycomb repressive complex 2-inhibitor 3-deazaneplanocin A Breast Cancer Res 11 2009 R63
76. S.H. Cho, J. Jeon, and S.I. Kim Personalized medicine in breast cancer: a systematic review J Breast Cancer 15 2012 265 272
77. M.J. Garnett, E.J. Edelman, S.J. Heidorn, C.D. Greenman, A. Dastur, and K.W. Lau Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 2012 570 575
78. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, and S. Kim The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity [Erratum appeared in Nature 2012, 492:290] Nature 483 2012 603 607
79. N. Turner, A. Tutt, and A. Ashworth Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 2004 814 819
80. C.J. Lord, and A. Ashworth The DNA damage response and cancer therapy Nature 481 2012 287 294
81. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, M. Santarosa, K.J. Dillon, I. Hickson, C. Knights, N.M. Martin, S.P. Jackson, G.C. Smith, and A. Ashworth Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
82. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N.J. Curtin, and T. Helleday Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [Erratum appeared in Nature 2007, 447:346] Nature 434 2005 913 917
83. F.L. Rehman, C.J. Lord, and A. Ashworth Synthetic lethal approaches to breast cancer therapy Nat Rev Clin Oncol 7 2010 718 724
84. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M.J. O'Connor, A. Ashworth, J. Carmichael, S.B. Kaye, J.H. Schellens, and J.S. de Bono Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
85. A. Tutt, M. Robson, J.E. Garber, S.M. Domchek, M.W. Audeh, J.N. Weitzel, M. Friedlander, B. Arun, N. Loman, R.K. Schmutzler, A. Wardley, G. Mitchell, H. Earl, M. Wickens, and J. Carmichael Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
86. T.O. Nielsen, F.D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, L.A. Akslen, J. Ragaz, A.M. Gown, C.B. Gilks, M. van de Rijn, and C.M. Perou Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374
87. J. O'Shaughnessy, C. Osborne, J.E. Pippen, M. Yoffe, D. Patt, C. Rocha, I.C. Koo, B.M. Sherman, and C. Bradley Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 2011 205 214
88. J. O'Shaughnessy, L.S. Schwartzberg, M.A. Danso, H.S. Rugo, K. Miller, D.A. Yardley, R.W. Carlson, R.S. Finn, E. Charpentier, M. Freese, S. Gupta, A. Blackwood-Chirchir, and E.P. Winer A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) J Clin Oncol 29 15 Suppl 2011 1007
89. A.G. Patel, S.B. De Lorenzo, K.S. Flatten, G.G. Poirier, and S.H. Kaufmann Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro Clin Cancer Res 18 2012 1655 1662
90. L.L. Marotta, V. Almendro, A. Marusyk, M. Shipitsin, J. Schemme, S.R. Walker, N. Bloushtain-Qimron, J.J. Kim, S.A. Choudhury, R. Maruyama, Z. Wu, M. Gönen, L.A. Mulvey, M.O. Bessarabova, S.J. Huh, S.J. Silver, S.Y. Kim, S.Y. Park, H.E. Lee, K.S. Anderson, A.L. Richardson, T. Nikolskaya, Y. Nikolsky, X.S. Liu, D.E. Root, W.C. Hahn, D.A. Frank, and K. Polyak The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors J Clin Invest 121 2011 2723 2735
91. J. Veeck, S. Ropero, F. Setien, E. Gonzalez-Suarez, A. Osorio, J. Benitez, J.G. Herman, and M. Esteller BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors J Clin Oncol 28 2010 e563 e564
92. Y. Drew, E.A. Mulligan, W.T. Vong, H.D. Thomas, S. Kahn, S. Kyle, A. Mukhopadhyay, G. Los, Z. Hostomsky, E.R. Plummer, R.J. Edmondson, and N.J. Curtin Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2 J Natl Cancer Inst 103 2011 334 346
93. H. Kim, and A.D. D'Andrea Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway Genes Dev 26 2012 1393 1408
94. K.L. Bolton, G. Chenevix-Trench, C. Goh, S. Sadetzki, S.J. Ramus, B.Y. Karlan EMBRACE kConFab Investigators Cancer Genome Atlas Research Network Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JAMA 307 2012 382 390
95. D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich, A.K. Sood, and W. Zhang Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer [Erratum appeared in JAMA 2012, 307:363] JAMA 306 2011 1557 1565
96. A. Reles, W.H. Wen, A. Schmider, C. Gee, I.B. Runnebaum, U. Kilian, L.A. Jones, A. El-Naggar, C. Minguillon, I. Schönborn, O. Reich, R. Kreienberg, W. Lichtenegger, and M.F. Press Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer Clin Cancer Res 7 2001 2984 2997
97. O.A. Stefansson, A. Villanueva, A. Vidal, L. Martí, and M. Esteller BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer Epigenetics 7 2012 1225 1229
98. H.R. Chang, J. Glaspy, M.A. Allison, F.C. Kass, R. Elashoff, D.U. Chung, and J. Gornbein Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment Cancer 116 2010 4227 4237
99. D.P. Silver, A.L. Richardson, A.C. Eklund, Z.C. Wang, Z. Szallasi, Q. Li, N. Juul, C.O. Leong, D. Calogrias, A. Buraimoh, A. Fatima, R.S. Gelman, P.D. Ryan, N.M. Tung, A. De Nicolo, S. Ganesan, A. Miron, C. Colin, D.C. Sgroi, L.W. Ellisen, E.P. Winer, and J.E. Garber Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 2010 1145 1153
100. T. Byrski, R. Dent, P. Blecharz, M. Foszczynska-Kloda, J. Gronwald, T. Huzarski, C. Cybulski, E. Marczyk, R. Chrzan, A. Eisen, J. Lubinski, and S.A. Narod Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer Breast Cancer Res 14 2012 R110
101. N.C. Turner, and A.N. Tutt Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res 14 2012 115
102. K. Rhiem, B. Wappenschmidt, K. Bosse, H. Köppler, A.N. Tutt, and R.K. Schmutzler Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer Clin Oncol (R Coll Radiol) 21 2009 448 450
103. Y. Fan, B.H. Xu, P. Yuan, F. Ma, J.Y. Wang, X.Y. Ding, P. Zhang, Q. Li, and R.G. Cai Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer Ann Oncol 24 2013 1219 1225
104. J.R. Adams, N.F. Schachter, J.C. Liu, E. Zacksenhaus, and S.E. Egan Elevated PI3K signaling drives multiple breast cancer subtypes Oncotarget 2 2011 435 447
105. J.C. Bendell, J. Rodon, H.A. Burris, M. de Jonge, J. Verweij, D. Birle, D. Demanse, S.S. De Buck, Q.C. Ru, M. Peters, M. Goldbrunner, and J. Baselga Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors J Clin Oncol 30 2012 282 290
106. S. Banerji, K. Cibulskis, C. Rangel-Escareno, K.K. Brown, S.L. Carter, and A.M. Frederick Sequence analysis of mutations and translocations across breast cancer subtypes Nature 486 2012 405 409
107. L.S. Chuang, S.K. Lai, M. Murata-Hori, A. Yamada, H.Y. Li, J. Gunaratne, and Y. Ito RUNX3 interactome reveals novel centrosomal targeting of RUNX family of transcription factors Cell Cycle 11 2012 1938 1947
108. L. Van Neste, J.G. Herman, G. Otto, J.W. Bigley, J.I. Epstein, and W. Van Criekinge The epigenetic promise for prostate cancer diagnosis Prostate 72 2012 1248 1261
109. M.J. Fackler, K. Malone, Z. Zhang, E. Schilling, E. Garrett-Mayer, T. Swift-Scanlan, J. Lange, R. Nayar, N.E. Davidson, S.A. Khan, and S. Sukumar Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid Clin Cancer Res 12 2006 3306 3310
110. H. Fiegl, S. Millinger, E. Mueller-Holzner, C. Marth, C. Ensinger, A. Berger, H. Klocker, G. Goebel, and M. Widschwendter Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients Cancer Res 65 2005 1141 1145
111. J.H. Vissers, M. van Lohuizen, and E. Citterio The emerging role of polycomb repressors in the response to DNA damage J Cell Sci 125 2012 3939 3948